Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3-Reference-Cited by-同舟云学术

Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3

Published:2016-12-02 Issue:3 Volume:31 Page:477-482
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

van de Kerkhof P.¹,Guenther L.²³,Gottlieb A.B.⁴,Sebastian M.⁵,Wu J.J.⁶,Foley P.⁷⁸,Morita A.⁹,Goldblum O.¹⁰,Zhang L.¹⁰,Erickson J.¹⁰,Ball S.¹⁰,Rich P.¹¹

Affiliation:

1. Department of Dermatology; Radboud University Nijmegen Medical Centre; Nijmegen The Netherlands

2. Division of Dermatology; Department of Medicine; Western University; London ON Canada

3. Guenther Research, Inc.; London ON Canada

4. Department of Dermatology; New York Medical College; Valhalla NY USA

5. Private Practice Dermatologist; Mahlow Germany

6. Kaiser Permanente Los Angeles Medical Center; Los Angeles CA USA

7. Department of Medicine (Dermatology); The University of Melbourne; St Vincent's Hospital Melbourne; Fitzroy Vic. Australia

8. Department of Dermatology; Skin and Cancer Foundation; Carlton Vic. Australia

9. Department of Geriatric and Environmental Dermatology; Nagoya City University Graduate School of Medical Sciences; Nagoya Japan

10. Eli Lilly and Company; Indianapolis IN USA

11. Dermatology and Clinical Research; Oregon Health Science University; Portland OR USA

Funder

Basilea

Pfizer

Amgen

Eli Lilly and Company

AbbVie

Philips Lighting

Janssen-Cilag

Leo Pharma

Centocor

Novartis

Celgene

Levia

Merck

Xenoport

Dermia

Baxalta

Galderma

Regeneron Pharmaceuticals

Universidade Católica de Brasília

AstraZeneca

Coherus Biosciences

Dermira

Sandoz

Sun Pharmaceutical Industries

LEO/Peplin

Ascent

Clinuvel

Australian Ultraviolet Services

Roche

CSL

3M/iNova/Valeant

GSK/Stiefel

Abbott/AbbVie

Biogen Idec

Merck Serono

Schering-Plough

Wyeth/Pfizer

American Society for Parenteral and Enteral Nutrition

Bristol-Myers Squibb

Boehringer Ingelheim

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdv.14033/fullpdf

Reference20 articles.

1. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year;Rich;J Am Acad Dermatol,2008

2. Nail psoriasis, the unknown burden of disease;Klaassen;J Eur Acad Dermatol Venereol,2014

3. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients;De Jong;Dermatology,1996

4. Nail psoriasis;Farber;Cutis,1992

5. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy;Jiaravuthisan;J Am Acad Dermatol,2007

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What Is New in Nail Psoriasis?;Skin Appendage Disorders;2024-07-22

2. Effectiveness of ixekizumab for the treatment of moderate‐to‐severe plaque psoriasis with involvement of difficult‐to‐treat areas: A 52‐week multicenter retrospective study;The Journal of Dermatology;2024-01-31

3. Nail psoriasis in China: A prospective multicentre study;Journal of the European Academy of Dermatology and Venereology;2023-12-15

4. Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septennium;Immunotherapy;2023-10

5. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis;Cochrane Database of Systematic Reviews;2023-07-12